Biogen posts a solid quarter but chops drugs and quietly pays out $900M in legal settlement ahead of closely watched readout
Biogen on Wednesday posted a strong second quarter, and increased its revenue guidance for the rest of the year, which the company said was driven …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
